Eli Lilly's (LLY) new COVID-19 treatment helped the drugmaker's fourth-quarter profit surge even though U.S. regulators approved its use late in the quarter. The antibody treatment bamlanivimab brought in $850 million in U.S. sales for Lilly after the Food and Drug Administration authorized emergency use in November for patients
"We are well-positioned for the future and will emerge from the pandemic as an even stronger company,"
Popular News Stories
Related News
Eli Lilly Profit Rises, Helped by Covid-19 Drug Sales
Eli Lilly and Co. reported a 41% rise in its quarterly profit on Friday, boosted by strong sales of its Covid-19 antibody treatment and higher demand for its diabetes...
Wall Street Journal 2021-01-29, 15:02Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails
Eli Lilly released more positive data on its Covid-19 antibody therapies. is back with another round of promising data on its Covid-19 antibody therapies. This time, the...
Barrons 2021-01-26, 15:14Eli Lilly profit beats estimates on demand for cancer, diabetes drugs
(Reuters) -Eli Lilly and Co posted a 41.5% rise in quarterly profit on Friday, helped by demand for its diabetes and cancer drugs, and as it benefited from the U.S....
Metro USA 2021-01-29, 12:54Glaxo, Eli Lilly join forces to test covid-19 antibody cocktail
GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can...

Caterpillar 4Q sales slip, but results top Wall Street
Caterpillar’s fourth-quarter sales dropped 15% as an unchecked pandemic continued to sap demand for big machinery, but the damage was not as bad as most had expected. Sales...
San Francisco Chronicle 2021-01-29, 13:00Q4 2020 Lilly Press Release (Eli Lilly and Company)
) January 29, 2021 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Mark...
Public Technologies 2021-01-29, 15:04